A Class of Novel and Nonpeptide HIV-1 Protease Inhibitors
- Summary
- Purdue University researchers have designed and synthesized a novel class of HIV-1 protease inhibitors containing isophthalamide derivatives for the treatment of multidrug-resistant strains of HIV. These potent nonpeptide inhibitors are expected to possess improved pharmacological properties, are easy to synthesize in quantities, and will be further applicable for new drug development.
- Technology Benefits
- Novel HIV therapeutics with improved pharmacological propertiesEffective for the treatment of multidrug-resistant strains of HIV Simple chemical synthesis amenable to large-scale production
- Technology Application
- Medical/HealthcarePharmaceuticalsHIV/AIDS TreatmentDrug Development
- Detailed Technology Description
- Arun GhoshGhosh GroupPurdue Chemistry
- Countries
- United States
- Application No.
- 9,085,571
- *Abstract
-
- *Background
- The AIDS epidemic is one of the most challenging problems in medicine in the 21st century. A retrovirus designated human immunodeficiency virus (HIV) is the etiological agent of the acquired immune deficiency syndrome (AIDS), a complex disease that includes progressive destruction of the immune system and degeneration of the central and peripheral nervous system. Among many strategies to combat this disease, highly active antiretroviral therapy (HAART) with HIV protease inhibitors in combination with reverse transcriptase inhibitors continues to be the first-line treatment for control of HIV infection. This treatment regimen has definitely improved quality of life, enhanced HIV management, and halted the progression of the disease. Today, more people than ever before are living with HIV/AIDS thanks to this first-line treatment. However, despite the impressive success, there remain many challenges to treating this devastating disease, including decreasing both the toxicity and complexity of the treatment regimens. In addition, there is a growing population of patients that are developing multidrug-resistant strains of HIV, and there is ample evidence that these strains can be further transmitted.
- *IP Issue Date
- Jul 21, 2015
- *IP Type
- Divisional
- *Stage of Development
- Concept Developed
- *Web Links
- Purdue Office of Technology CommercializationPurdueInnovation and EntrepreneurshipArun GhoshGhosh GroupPurdue Chemistry
- Country/Region
- USA
For more information, please click Here
